Karen E Linder

This inventor holds 40 USPTO granted patents and 9 published patent applications, plus 6 CIPO patents and 4 EPO patents, primarily in Multivalent Constructs. Top assignees: Bracco International Bv, Bracco Suisse Sa, Bracco Imaging S.p.a.. Active years: 1991-2016.

USPTO Granted Patents = 40 (Patent Applications = 9)

% Patents Active = 47.5

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 6.6

ph-index = 14

Forward Citations = 855(Granted Patents)

Location History:

Highland Park, NJ (US) (1991 - 1993)
Kingston, NJ (US) (1995 - 2016)

Company Filing History:

13 out of 108

Bracco International Bv

Bracco Imaging S.p.a.

E. R. Squibb Sons, Inc.

patents

6. 2 out of 109

Bracco Diagnostics Inc.

where one patent can have more than one assignee

Years Active: 1991-2016

Loading Chart...

Areas of Expertise:

Multivalent Constructs

KDR Peptides

VEGF Binding

Gastrin Releasing Peptides

Endothelial Cell Targeting

Radiopharmaceuticals

Metal Complexes

Diagnostic Imaging

Therapeutic Applications

Compounds

Rhenium Complexes

Technetium Complexes

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9446155 - KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy (2016-09-20),

2. 9408926 - KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy (2016-08-09),

3. 9056138 - Multivalent constructs for therapeutic and diagnostic applications (2015-06-16),

4. 8663603 - Multivalent constructs for therapeutic and diagnostic applications (2014-03-04),

5. 8642010 - KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy (2014-02-04),

6. 8632753 - Multivalent constructs for therapeutic and diagnostic applications (2014-01-21),

7. 8623822 - KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy (2014-01-07),

8. 8444954 - Gastrin releasing peptide compounds (2013-05-21),

9. 8420053 - Gastrin releasing peptide compounds (2013-04-16),

10. 8420050 - Gastrin releasing peptide compounds (2013-04-16),

11. 8414864 - Gastrin releasing peptide compounds (2013-04-09),

12. 8409165 - Tabletop drug dispensing vial access adapter (2013-04-02),

13. 8263739 - Compounds for targeting endothelial cells, compositions containing the same and methods for their use (2012-09-11),

14. 7922998 - Gastrin releasing peptide compounds (2011-04-12),

15. 7910088 - Multivalent constructs for therapeutic and diagnostic applications (2011-03-22),

Title: Innovations by Karen E Linder in Angiogenesis Treatment

Introduction

Karen E Linder, based in Kingston, NJ, is a prolific inventor with an impressive portfolio of 40 patents. His contributions to the field of biotechnology, particularly in the area of angiogenesis, highlight his significant impact on medical innovation and therapeutic solutions.

Latest Patents

Among his most notable recent inventions are the KDR and VEGF/KDR binding peptides and their applications in both diagnosis and therapy. These innovations provide a range of polypeptides, peptide dimers, and multimeric complexes designed to bind to the KDR or VEGF/KDR complex. They are instrumental in treating, detecting, isolating, or localizing angiogenesis, which is crucial in various medical conditions, notably cancer. These synthetic, isolated polypeptides exhibit high affinity binding capabilities and can be used alongside contrast agents for monitoring and evaluating treatment effectiveness against diseases associated with angiogenesis or endothelial cell hyperproliferation.

Career Highlights

Karen E Linder has had a remarkable career, contributing to companies such as Bracco International Bv and Bracco Suisse Sa. His expertise has been vital in advancing the knowledge and application of peptide-based therapies and diagnostics in the medical field.

Collaborations

Throughout his career, Karen has collaborated with numerous talented professionals, including Kondareddiar Ramalingam and Adrian D Nunn. These collaborations have further enhanced his research and development efforts, leading to significant advancements in treatment protocols.

Conclusion

Karen E Linder's work exemplifies the spirit of innovation, particularly in developing therapeutic solutions for angiogenesis-related conditions. His numerous patents underscore his contributions to medical science and the potential for his inventions to improve patient outcomes in the future.